TARDBP and proteostasis deficiencies: Although the clinical subgroups included were reliably associated with either tau or TDP-43, and any subgroups that were known to involve both pathological mechanisms were eliminated to reduce confounding factors, future studies would hopefully include only biomarker proven proteinopathies.